Gilead Sciences Announces First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Lowered to $76 at Barclays
April 29, 2024 5:23 AM EDTBarclays analyst Carter Gould lowered the price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $80.00) while maintaining a Equalweight rating.
The analyst comments "'25 HIV zero-growth messaging, puts onus on cell therapy and seladelpar launch to deliver overall top-line growth. Focus... More
